Published on
Jun 18, 2025
CGRP Therapy Atogepant Outperforms Topiramate in Head-to-Head TEMPLE Trial
Newly announced data from the phase 3 TEMPLE trial, a head-to-head study comparing atogepant (Qulipta; AbbVie) to topiramate (Topamax), 2 FDA-approved migraine medications, showed that atogepant met its primary end point, outperforming the anticonvulsant …
Source:
NeurologyLive
-
Neutral
